+ All Categories
Home > Health & Medicine > Lecturas recomendadas neuro oncología 2012

Lecturas recomendadas neuro oncología 2012

Date post: 23-Jan-2015
Category:
Upload: inub
View: 162 times
Download: 0 times
Share this document with a friend
Description:
 
4
1 RedLANO e –Journal 2 0 1 2 www.redlano.org (Epub ahead of print) Ciencias básicas Duncan, C. G. et. al. A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation. Geno- me Res. 2012 Dec;22(12):2339-55. Lu, C. et. al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012 Feb 15;483(7390):474-8. Sturm, D. et. al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell. 2012 Oct 16;22(4):425-37. Turcan, S. et. al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 2012 Feb 15;483(7390):479-83. Chen, J. et. al. A restricted cell population propagates glio- blastoma growth after chemotherapy. Nature. 2012 Aug 23;488(7412):522-6. Friedmann-Morvinski, D. et. al. Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice. Science. 2012 Nov 23;338(6110):1080-4. Muller, F. L. et. al. Passenger deletions generate therapeutic vulnerabilities in cancer. Nature. 2012 Aug 16;488(7411):337- 42. LECTURAS RECOMENDADAS NEURO–ONCOLOGÍA 2012 Sasaki, M. et. al. IDH1(R132H) mutation increases murine hae- matopoietic progenitors and alters epigenetics. Nature. 2012 Aug 30;488(7413):656-9. Singh, D. et. al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science. 2012 Sep 7;337(6099):1231-5. Snuderl, M. et. al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell. 2011 Dec 13;20(6):810-7. Vivanco, I. et. al. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov. 2012 May;2(5):458-71. Koivunen, P. et. al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature. 2012 Feb 15;483(7390):484-8. Neuro-oncología pediátrica Jones, D. T. et. al. Dissecting the genomic complexi- ty underlying medulloblastoma. Nature. 2012 Aug 2;488(7409):100-5. Northcott, P. A. et. al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature. 2012 Aug 2;488(7409):49-56.
Transcript
Page 1: Lecturas recomendadas neuro oncología 2012

1

RedLANO e–Journal2 0 1 2 w w w . r e d l a n o . o r g( E p u b a h e a d o f p r i n t )

Ciencias básicas

Duncan, C. G. et. al. A heterozygous IDH1R132H/WT mutation

induces genome-wide alterations in DNA methylation. Geno-

me Res. 2012 Dec;22(12):2339-55.

Lu, C. et. al. IDH mutation impairs histone demethylation

and results in a block to cell differentiation. Nature. 2012 Feb

15;483(7390):474-8.

Sturm, D. et. al. Hotspot mutations in H3F3A and IDH1 define

distinct epigenetic and biological subgroups of glioblastoma.

Cancer Cell. 2012 Oct 16;22(4):425-37.

Turcan, S. et. al. IDH1 mutation is sufficient to establish the

glioma hypermethylator phenotype. Nature. 2012 Feb

15;483(7390):479-83.

Chen, J. et. al. A restricted cell population propagates glio-

blastoma growth after chemotherapy. Nature. 2012 Aug

23;488(7412):522-6.

Friedmann-Morvinski, D. et. al. Dedifferentiation of neurons

and astrocytes by oncogenes can induce gliomas in mice.

Science. 2012 Nov 23;338(6110):1080-4.

Muller, F. L. et. al. Passenger deletions generate therapeutic

vulnerabilities in cancer. Nature. 2012 Aug 16;488(7411):337-

42.

LECTURAS RECOMENDADAS NEURO–ONCOLOGÍA 2012

Sasaki, M. et. al. IDH1(R132H) mutation increases murine hae-

matopoietic progenitors and alters epigenetics. Nature. 2012

Aug 30;488(7413):656-9.

Singh, D. et. al. Transforming fusions of FGFR and TACC genes

in human glioblastoma. Science. 2012 Sep 7;337(6099):1231-5.

Snuderl, M. et. al. Mosaic amplification of multiple receptor

tyrosine kinase genes in glioblastoma. Cancer Cell. 2011 Dec

13;20(6):810-7.

Vivanco, I. et. al. Differential sensitivity of glioma- versus lung

cancer-specific EGFR mutations to EGFR kinase inhibitors.

Cancer Discov. 2012 May;2(5):458-71.

Koivunen, P. et. al. Transformation by the (R)-enantiomer of

2-hydroxyglutarate linked to EGLN activation. Nature. 2012

Feb 15;483(7390):484-8.

Neuro-oncología pediátrica

Jones, D. T. et. al. Dissecting the genomic complexi-

ty underlying medulloblastoma. Nature. 2012 Aug

2;488(7409):100-5.

Northcott, P. A. et. al. Subgroup-specific structural variation

across 1,000 medulloblastoma genomes. Nature. 2012 Aug

2;488(7409):49-56.

Page 2: Lecturas recomendadas neuro oncología 2012

2

RedLANO e–Journal2 0 1 2 w w w . r e d l a n o . o r g( E p u b a h e a d o f p r i n t )

Wu, G. et. al. Somatic histone H3 alterations in pediatric

diffuse intrinsic pontine gliomas and non-brainstem glio-

blastomas. Nat Genet. 2012 Jan 29;44(3):251-3.

Robinson, G. et. al. Novel mutations target distinct subgroups

of medulloblastoma. Nature. 2012 Aug 2;488(7409):43-8.

Schwartzentruber, J. et. al. Driver mutations in histone H3.3

and chromatin remodelling genes in paediatric glioblasto-

ma. Nature. 2012 Jan 29;482(7384):226-31.

Patología en tumores cerebrales

Jiao, Y. et. al. Frequent ATRX, CIC, and FUBP1 mutations refi-

ne the classification of malignant gliomas. Oncotarget. 2012

Jul;3(7):709-22.

Liu, X. Y. et. al. Frequent ATRX mutations and loss of expres-

sion in adult diffuse astrocytic tumors carrying IDH1/IDH2

and TP53 mutations. Acta Neuropathol. 2012 Aug 12.

Lu, K. V. et. al. VEGF inhibits tumor cell invasion and mesen-

chymal transition through a MET/VEGFR2 complex. Cancer

Cell. 2012 Jul 10;22(1):21-35.

Cirugía

Castellano, A. et. al. Role of diffusion tensor magnetic reso-

nance tractography in predicting the extent of resection in

glioma surgery. Neuro Oncol. 2012 Feb;14(2):192-202.

De Witt Hamer, P. C. et. al. Impact of intraoperative stimu-

lation brain mapping on glioma surgery outcome: a meta-

analysis. J Clin Oncol. 2012 Jul 10;30(20):2559-65.

Gans, J. H. et. al. The Role of Radiosurgery to the Tumor Bed

After Resection of Brain Metastases. Neurosurgery. 2012 Nov

30.

Hofmann, B. M. et. al. Results after treatment of craniopharyn-

giomas: further experiences with 73 patients since 1997. J

Neurosurg. 2012 Feb;116(2):373-84.

Radioterapia

Tsien, C. I. et. al. Concurrent temozolomide and dose-esca-

lated intensity-modulated radiation therapy in newly diag-

nosed glioblastoma. Clin Cancer Res. 2012 Jan 1;18(1):273-9.

Pallud, J. et. al. Dynamic imaging response following radia-

tion therapy predicts long-term outcomes for diffuse low-

grade gliomas. Neuro Oncol. 2012 Apr;14(4):496-505.

Metastasis cerebrales

Soffietti, R. et. al. A European Organisation for Research and

Treatment of Cancer Phase III Trial of Adjuvant Whole-Brain

Radiotherapy Versus Observation in Patients With One to

Three Brain Metastases From Solid Tumors After Surgical Re-

section or Radiosurgery: Quality-of-Life Results. J Clin Oncol.

2013 Jan 1;31(1):65-72.

Page 3: Lecturas recomendadas neuro oncología 2012

3

RedLANO e–Journal2 0 1 2 w w w . r e d l a n o . o r g( E p u b a h e a d o f p r i n t )

Falchook, G. S. et. al. Dabrafenib in patients with melanoma,

untreated brain metastases, and other solid tumours: a phase

1 dose-escalation trial. Lancet. 2012 May 19;379(9829):1893-

901.

Long, GV. et. al. Dabrafenib in patients with Val600Glu or

Val600Lys BRAF-mutant melanoma metastatic to the brain

(BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet

Oncol. 2012 Nov;13(11):1087-95.

Margolin, K. et. al. Ipilimumab in patients with melanoma

and brain metastases: an open-label, phase 2 trial. Lancet

Oncol. 2012 May;13(5):459-65.

Preusser, M. et. al. Trial design on prophylaxis and treatment

of brain metastases: Lessons learned from the EORTC Bra-

in Metastases Strategic Meeting 2012. Eur J Cancer. 2012

Dec;48(18):3439-47.

Tsao, M. N. et. al. Radiotherapeutic and surgical manage-

ment for newly diagnosed brain metastasis(es): An Ameri-

can Society for Radiation Oncology evidence-based gui-

deline. Practical Radiation Oncology. 2012; 2(3): 210-225.

http://download.journals.elsevierhealth.com/pdfs/jour-

nals/1879-8500/PIIS1879850011003808.pdf

Gliomas de alto grado

Cairncross G, et. al Phase III Trial of Chemoradiotherapy for

Anaplastic Oligodendroglioma: Long-Term Results of RTOG

9402. J Clin Oncol. 2012 Oct 15. [Epub ahead of print]

Van den Bent MJ, et. al. Adjuvant Procarbazine, Lomustine,

and Vincristine Chemotherapy in Newly Diagnosed Ana-

plastic Oligodendroglioma: Long-Term Follow-Up of EORTC

Brain Tumor Group Study 26951. J Clin Oncol. 2012 Oct 15.

[Epub ahead of print]

Malmström A. et. al. Temozolomide versus standard 6-week

radiotherapy versus hypofractionated radiotherapy in pa-

tients older than 60 years with glioblastoma: the Nordic ran-

domised, phase 3 trial. Lancet Oncol. 2012 Sep;13(9):916-26.

Wick, W. et. al. Temozolomide chemotherapy alone versus

radiotherapy alone for malignant astrocytoma in the elderly:

the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012

Jul;13(7):707-15. doi: 10.1016/S1470-2045(12)70164-X. Epub

2012 May 10.

Gliomas de bajo grado

Jakola, A. S. et. al. Comparison of a strategy favoring early

surgical resection vs a strategy favoring watchful waiting in

low-grade gliomas. JAMA. 2012 Nov 14;308(18):1881-8.

Pallud, J. et. al. Quantitative morphological magnetic reso-

nance imaging follow-up of low-grade glioma: a plea for

systematic measurement of growth rates. Neurosurgery.

2012 Sep;71(3):729-39; discussion 739-40.

Potts, M. B. et. al. Natural history and surgical management

of incidentally discovered low-grade gliomas. J Neurosurg.

2012 Feb;116(2):365-72.

Englot, D. J. et. al. Extent of surgical resection predicts seizu-

re freedom in low-grade temporal lobe brain tumors. Neuro-

surgery. 2012 Apr;70(4):921-8.

Page 4: Lecturas recomendadas neuro oncología 2012

4

RedLANO e–Journal2 0 1 2 w w w . r e d l a n o . o r g( E p u b a h e a d o f p r i n t )

Linfoma del sistema nervioso central

Ghesquières H, et. al. Evidence of time-dependent prognos-

tic factors predicting early death but not long-term outco-

me in primary CNS lymphoma: a study of 91 patients. Hema-

tol Oncol. 2012 Aug 9.

Gonzalez-Aguilar A, et. al. Recurrent mutations of MYD88

and TBL1XR1 in primary central nervous system lymphomas.

Clin Cancer Res. 2012 Oct 1;18(19):5203-11.

Mappa S, et. al. Salvage chemoimmunotherapy with rituxi-

mab, ifosfamide and etoposide (R-IE regimen) in patients

with primary CNS lymphoma relapsed or refractory to high-

dose methotrexate-based chemotherapy. Hematol Oncol.

2012 Nov 14.

Roth P, et. al. Outcome of elderly patients with primary CNS

lymphoma in the G-PCNSL-SG-1 trial. Neurology. 2012 Aug

28;79(9):890-6.

Welch MR, et. al. Outcomes of the oldest patients with pri-

mary CNS lymphoma treated at Memorial Sloan-Kettering

Cancer Center. Neuro Oncol. 2012 Oct;14(10):1304-11.

Cuidados y soporte paliativo en neuro-oncología

Chochinov, H. M. et. al. The Patient Dignity Inventory:

applications in the oncology setting. J Palliat Med. 2012

Sep;15(9):998-1005.

Colen, C. B. and Allcut, E. Quality of life and outcomes in

glioblastoma management. Neurosurg Clin N Am 23 (2012)

507-513.

Efficace, F. and Taphoorn, M. Methodological issues in de-

signing and reporting health-related quality-of-life in cancer

trials: the challenge of brain cancer studies. J Neurooncolo-

gy (2012) 108: 221-226

Ford, E. et. al. Systematic review of supportive care needs

in patients with primary malignant brain tumours. Neuro-

Oncology 14 (4): 392-404, 2012

Gofton, T. E. et. al. Identifying the palliative care needs of

patients living with cerebral tumours and metastases : a re-

trospective analysis. J Neurooncology (2012) 108: 527-534

de Groot, M. et. al. Epilepsy in patients with a brain tumour:

focal epilepsy requires focused treatment. Brain. 2012

Apr;135 (Pt4):1002-16.

Rooney, A. G. et. al. Frequency, clinical associations, and lon-

gitudinal course of major depressive disorder in adults with

cerebral glioma. J Clin Oncol. 2011 Nov 10;29(32):4307-12.


Recommended